Page 149 - 2021_12-Haematologica-web

Megakaryocytic activation and fibrotic evolution of MPN
cythemia vera and post-essential thrombo- cythemia myelofibrosis: a consensus state- ment from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438.
22.Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC. International council for stan- dardization in hematology. ICSH guide- lines for the standardization of bone mar- row specimens and reports. Int J Lab Hematol. 2008;30(5):349-364.
23.Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
24.Afkhami M, Vergara-Lluri M, Brynes RK, Siddiqi IN. Peripheral blood smears, bone marrow aspiration, trephine and clot biop- sies: methods and protocols. Methods Mol
Biol. 2014;1180:257-269.
25.Martini M, Cenci T, D'Alessandris GQ, et
al. Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prog- nosis as a consequence of an inhibition of angiogenesis. Cancer. 2013;119(5):1004- 1012.
26.Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574-1579.
27. Cerquozzi S, Tefferi A. Blast transforma- tion and fibrotic progression in poly- cythemia vera and essential thrombo- cythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5(11): e366.
28.Ciurea SO, Merchant D, Mahmud N, et al.
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110(3):986-993.
29.Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myelo- proliferative syndrome in mice. Blood. 1997;90(11):4369-4383.
30. Wen QJ, Yang Q, Goldenson B, et al. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015;21(12):1473-1480.
31.Malara A, Gruppi C, Abbonante V, et al. EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflamma- tion in bone marrow fibrosis. J Exp Med. 2019;216(3):587-604.
32.Palandri F, Sabattini E, Maffioli M. Treating early-stage myelofibrosis. Ann Hematol. 2019;98(2):241-253.
haematologica | 2021; 106(12)
3169